Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Kopen Sugar Free 125 mg/5 ml Powder for Oral Solution
Medicines register · Ireland

Kopen Sugar Free 125 mg/5 ml Powder for Oral Solution

Authorisation PA1418/014/001 · Athlone Pharmaceuticals Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Athlone Pharmaceuticals Limited (all products →)
Active substance
Phenoxymethylpenicillin
Clinical trials
2 clinical trials →
Dosage form
Powder for oral solution
Route of administration
Oral use
ATC codes
J01CE, J01CE02
First authorised
11/04/1988
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Not Currently Available

Phenoxymethylpenicillin: supply and approvals

8 authorised products on the HPRA list contain Phenoxymethylpenicillin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
1 supply notice, e.g. Pen 0,4 Mega TS - 1 A Pharma (30 Sep 2026 to 30 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 38 years (since 11 April 1988). The HPRA list marks it as marketed in Ireland.

Other medicines with Phenoxymethylpenicillin in Ireland

1 other product on the HPRA list contains Phenoxymethylpenicillin, from 1 licence holder; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Kopen Sugar Free 250 mg/5 ml Powder for Oral SolutionAthlone Pharmaceuticals LimitedNational authorisation (PA)Marketed

Other substances in ATC group J01CE

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 3 other active substances share the group J01CE with this product:

PHENOXYMETHYLPENICILLIN CALCIUM (3) · Phenoxymethylpenicillin potassium (3) · Benzylpenicillin Sodium (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Athlone Pharmaceuticals Limited holds 30 products on the HPRA list, with 17 different active substances; 17 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.